natgillin/translations-raw huggingface dataset:
Treatment and metaphylaxis of Enzootic Pneumonia caused by Mycoplasma hyopneumoniae, including infections complicated by Pasteurella multocida susceptible to tiamulin.
Zdravljenje in metafilaksa enzootske pljučnice, ki jo povzroča Mycoplasma hyopneumoniae, vključno z okužbami, ki se zapletejo zaradi bakterije Pasteurella multocida, občutljive na tiamulin.
ii) Treatment of Porcine Colonic Spirochaetosis (colitis) caused by Brachyspira pilosicoli susceptible to tiamulin.
ii) Zdravljenje spirohetoze debelega črevesa (kolitisa) pri prašičih, ki jo povzroča Brachyspira pilosicoli, občutljiva na tiamulin.
iii) Treatment of Porcine Proliferative Enteropathy (ileitis) caused by Lawsonia intracellularis susceptible to tiamulin.
iii) Zdravljenje proliferativne enteropatije (ileitisa) pri prašičih, ki jo povzroča Lawsonia intracellularis, občutljiva na tiamulin.
From these data the CVMP concluded that Denagard 45% at a dose of 8.8 mg tiamulin hydrogen fumarate (equivalent to 19.6 mg of product)/kg body weight for three to five consecutive days would be efficacious in the treatment of Swine Dysentery caused by B. hyodysenteriae.
Na podlagi teh podatkov je odbor CVMP zaključil, da je zdravilo Denagard 45% v odmerku 8,8 mg tiamulinijevega hidrogenfumarata (kar ustreza 19,6 mg zdravila)/kg telesne mase v obdobju treh do petih dni zaporedoma učinkovito pri zdravljenju prašičje dizenterije, ki jo povzroča B. hyodysenteriae.
Pigs, chickens, turkeys
meleagridis, pri piščancih in puranih.
Denagard 450 mg/g Granulado Oral
Denagard 450 mg/g Granulado Oral tiamulinijev hidrogenfumarat
In European isolates tiamulin was highly active against M. hyopneumoniae, with MIC50 of 0.016 µg/ml, MIC90 of 0.062 µg/ml, and a MIC range of 0.002-0.125 µg/ml (MycoPath I project, 2014).
0,016 µg/ml, MIK90 0,062 µg/ml in razponom MIK med 0,002 in 0,125 µg/ml (projekt MycoPath I, 2014).
Denagard 45% Granulat Tiamulin hydrogen fumarate
Denagard 45% Granulat tiamulinijev hidrogenfumarat
Denagard 45% WSG Tiamulin hydrogen fumarate
Denagard 45% WSG tiamulinijev hidrogenfumarat
From these data the CVMP concluded that Denagard 45% at a dose of 8.8 mg tiamulin hydrogen fumarate (equivalent to 19.6 mg of product)/kg body weight for three to five consecutive days would be efficacious in the treatment of Porcine Colonic Spirochaetosis (colitis) caused by B. pilosicoli.
Na podlagi teh podatkov je odbor CVMP zaključil, da je zdravilo Denagard 45% v odmerku 8,8 mg tiamulinijevega hidrogenfumarata (kar ustreza 19,6 mg zdravila)/kg telesne mase v obdobju treh do petih dni zaporedoma učinkovito pri zdravljenju spirohetoze debelega črevesa (kolitisa) pri prašičih, ki jo povzroča B. pilosicoli.
- Treatment of Pleuropneumonia caused by Actinobacillus pleuropneumoniae susceptible to tiamulin.
- Zdravljenje plevropnevmonije, ki jo povzroča Actinobacillus pleuropneumoniae, občutljiv na tiamulin.
Treatment and metaphylaxis of Chronic Respiratory Disease caused by Mycoplasma gallisepticum and Airsacculitis and Infectious Synovitis caused by Mycoplasma synoviae susceptible to tiamulin.
Zdravljenje in metafilaksa kronične bolezni dihal, ki jo povzroča Mycoplasma gallisepticum, ter vnetja zračnih vreč in infekcijskega sinovitisa, ki ju povzroča Mycoplasma synoviae, občutljiva na tiamulin.
Treatment of Pleuropneumonia caused by Actinobacillus pleuropneumoniae susceptible to tiamulin.
Zdravljenje plevropnevmonije, ki jo povzroča Actinobacillus pleuropneumoniae, občutljiv za tiamulin.
v) Treatment of Pleuropneumonia caused by Actinobacillus pleuropneumoniae susceptible to tiamulin.
v) Zdravljenje plevropnevmonije, ki jo povzroča Actinobacillus pleuropneumoniae, občutljiv na tiamulin.
- Treatment of Porcine Colonic Spirochaetosis (colitis) caused by Brachyspira pilosicoli susceptible to tiamulin.
- Zdravljenje spirohetoze debelega črevesa (kolitisa), ki jo povzroča Brachyspira pilosicoli, občutljiva na tiamulin.
- Treatment of Porcine Proliferative Enteropathy (ileitis) caused by Lawsonia intracellularis susceptible to tiamulin.
- Zdravljenje proliferativne enteropatije (ileitisa), ki jo povzroča Lawsonia intracellularis, občutljiva na tiamulin.
iv) For the treatment and metaphylaxis of Enzootic Pneumonia caused by Mycoplasma hyopneumoniae, including infections complicated by Pasteurella multocida susceptible to tiamulin.
iv) Za zdravljenje in metafilakso enzootske pljučnice, ki jo povzroča Mycoplasma hyopneumoniae, in njenih zapletov, ki jih povzroča Pasteurella multocida, občutljiva na tiamulin.
450 mg/g Granules for use in drinking water
450 mg/g zrnca prašiči peroralna uporaba za dajanje v vodo za pitje
Mean body weight (kg) of animals to be treated
povprečna telesna masa (kg)
Treatment of Porcine Colonic Spirochaetosis (colitis) caused by Brachyspira pilosicoli susceptible to tiamulin.
Zdravljenje spirohetoze debelega črevesa (kolitisa) pri prašičih, ki jo povzroča Brachyspira pilosicoli, občutljiva za tiamulin.
iv) Treatment and metaphylaxis of Enzootic Pneumonia caused by Mycoplasma hyopneumoniae, including infections complicated by Pasteurella multocida susceptible to tiamulin.
iv) Zdravljenje in metafilaksa enzootske pljučnice, ki jo povzroča Mycoplasma hyopneumoniae, in njenih zapletov, ki jih povzroča Pasteurella multocida, občutljiva na tiamulin.
Nine older artificial infection studies and three old field studies were presented to support the indication ‘treatment and metaphylaxis of Chronic Respiratory Disease caused by M. gallisepticum'.
V podporo indikaciji „zdravljenje in metafilaksa kronične respiratorne bolezni, ki jo povzroča M. gallisepticum“ so predložili devet starejših študij z umetno okužbo in tri stare terenske študije.
DENAGARD 45% Tiamulin hydrogen fumarate
DENAGARD 45% tiamulinijev hidrogenfumarat
Benefit assessment
Učinkovina Jakost
- Dosage: 20 mg tiamulin hydrogen fumarate (equivalent to 44.4 mg of product)/kg body weight administered daily for 5 consecutive days.
- Odmerjanje: Dnevni odmerek 20 mg tiamulinijevega hidrogenfumarata (kar ustreza 44,4 mg zdravila)/kg telesne mase v pitni vodi za prašiče v obdobju 5 dni zaporedoma.
4.9 Amounts to be administered and administration route
4.9 Odmerjanje in pot uporabe Navodila za pripravo raztopine zdravila:
Special precautions for use in animals
Ime zdravila za uporabo v veterinarski medicini
QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Tiamulin hydrogen fumarate
Učinkovina: tiamulinijev hidrogenfumarat
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali)
v) For the treatment of Pleuropneumonia caused by Actinobacillus pleuropneumoniae susceptible to tiamulin.
v) Za zdravljenje plevropnevmonije, ki jo povzroča Actinobacillus pleuropneumoniae, občutljiv na tiamulin.
Date on which the label was last approved To be completed nationally.
Datum zadnje odobritve stične ovojnine
Pigs, chickens (broilers, laying and breeding hens), turkeys
zrnca prašiči, piščanci, purani dajanje v vodo za pitje
Airsacculitis and Infectious Synovitis caused by Mycoplasma synoviae susceptible to tiamulin.
Mycoplasma gallisepticum, Mycoplasma synoviae in Mycoplasma meleagridis, občutljive na tiamulin.
Further information on Leucogen can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Nadaljnje informacije o zdravilu Leucogen so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The European Medicines Agency decided that Leucogen's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je odločila, da so koristi zdravila Leucogen večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Leucogen received a marketing authorisation valid throughout the EU for Leucogen on 17 June 2009.
Zdravilo Leucogen je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 17. junija 2009.
Other information about Leucogen
Druge informacije o zdravilu Leucogen
Leucogen is a vaccine.
Zdravilo Leucogen je cepivo.
The vaccine is used to prevent the disease signs and persistent viraemia (the presence of FeLV in the blood).
Cepivo se uporablja za preprečevanje znakov bolezni in preprečevanje trajne viremije (prisotnosti virusa FeLV v krvi).
Why is Leucogen authorised in the EU?
Zakaj je zdravilo Leucogen odobreno v EU?
For the full list of restrictions and all side effects reported with Leucogen, see the package leaflet.
Za celoten seznam omejitev in neželenih učinkov, o katerih so poročali pri uporabi zdravila Leucogen, glejte navodilo za uporabo.
The most common side effects with Leucogen (which may affect up to 1 in 10 cats) are a moderate and short-lived local reaction (<2 cm) after the first injection which resolves without treatment within 3 to 4 weeks, raised body temperature (lasting 1 to 4 days), apathy (listlessness) and digestive disturbances.
Najpogostejši neželeni učinki zdravila Leucogen (ki lahko prizadenejo največ 1 mačko od 10) so zmerna in kratkotrajna lokalna reakcija (< 2 cm) po prvi injekciji, ki izzveni v treh ali štirih tednih brez zdravljenja, povišana telesna temperatura (ki traja od enega do štirih dni), apatija (ravnodušnost) in prebavne motnje.
What benefits of Leucogen have been shown in studies?
Kakšne koristi je zdravilo Leucogen izkazalo v študijah?
What is Leucogen and what is it used for?
Kaj je zdravilo Leucogen in za kaj se uporablja?
An overview of Leucogen and why it is authorised in the EU
Pregled zdravila Leucogen in zakaj je odobreno v EU
What are the risks associated with Leucogen?
Kakšna tveganja so povezana z zdravilom Leucogen?
Leucogen must not be used in pregnant cats.
Zdravilo Leucogen se ne sme uporabljati pri brejih mačkah.
Feline leukaemia is an infectious disease of cats which affects the immune system and is caused by the feline leukaemia virus (FeLV).
Mačja levkemija je nalezljiva bolezen mačk, ki prizadene imunski sistem in jo povzroča virus mačje levkemije (FeLV).
In cases where the kitten may have antibodies passed from the mother, a third injection can be given from 15 weeks of age.
Če je mlada mačka od matere prejela protitelesa, lahko tretjo injekcijo prejme od 15 tednov starosti dalje.
Leucogen is available as a suspension for injection and can only be obtained with a prescription.
Zdravilo Leucogen je na voljo v obliki suspenzije za injiciranje, predpisovanje in izdaja zdravila pa je le na recept.
Leucogen contains small amounts of a protein from the outer layer of the virus called ‘envelope p45 protein'.
Zdravilo Leucogen vsebuje majhno količino beljakovine zunanje ovojnice virusa, imenovano „beljakovina ovojnice p45“.
Following the first booster vaccination protection lasts 3 years.
Po prvem obnovitvenem cepljenju traja zaščita tri leta.
When a cat is given the vaccine the cat's immune system recognises the protein as ‘foreign' and makes antibodies against it.
Ko mačka prejme cepivo, imunski sistem prepozna beljakovino kot tujek in proti njej tvori protitelesa.
Protection starts 3 weeks after the primary course of vaccination and lasts one year.
Zaščita je učinkovita tri tedne po prvem sklopu cepljenja in traja eno leto.
In a second study, kittens aged 8-9 weeks were given an initial vaccination course of a combination vaccine consisting of one dose of Feligen RCP (against feline rhinotracheitis virus, feline calicivirus and feline panleucopenia virus) with one dose of Leucogen.
V drugi študiji so mlade mačke, stare od osem do devet tednov, prejele začetni sklop cepljenja s kombiniranim cepivom, ki je vsebovalo en odmerek zdravila Feligen RCP (cepiva proti virusu mačjega rinotraheitisa, mačjemu kalicivirusu in virusu mačje panlevkopenije) in en odmerek zdravila Leucogen.
How is Leucogen used?
Kako se zdravilo Leucogen uporablja?
In one field study kittens aged 8 to 9 weeks were given an initial vaccination course of Leucogen with 2 injections 3 weeks apart and an annual booster injection 1 year later.
V terenski študiji so mlade mačke, stare od osem do devet tednov, prejele začetni sklop cepljenja z zdravilom Leucogen, in sicer dve injekciji s tritedenskim razmikom, eno leto pozneje pa letno obnovitveno injekcijo.
Leucogen is a veterinary vaccine used in cats from eight weeks of age to protect them against feline leukaemia.
Zdravilo Leucogen je cepivo za uporabo v veterinarski medicini, ki se za zaščito pred mačjo levkemijo uporablja pri mačkah, starih osem tednov in več.
Leucogen also contains aluminium hydroxide gel and extract of Quillaja saponaria as adjuvants
Zdravilo Leucogen kot adjuvansa (sestavini, ki spodbudita imunski odziv) vsebuje tudi gel aluminijevega hidroksida in izvleček Quillaja saponaria.
How does Leucogen work?
Kako zdravilo Leucogen deluje?
Content (concentration)
Innehåll (koncentration)
Strength Pharmaceutical Form
Styrka Läkemedelsform Administreringssätt
Immediate Packaging
Innerförpackning
1 pre-filled pen
1 förfylld injektionspenna
Pack size
Förpackningsstorle k
MA (EU) number (Invented) name
(Läkemedlets) namn
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila European Medicines Agency (http://www.ema.europa.eu/).
If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.
Če po 7 dneh ni nobenih znakov izboljšanja, mora veterinar ponovno oceniti zdravljenje.
If you notice any side effects even those not already listed in this leaflet, or you think that the medicine has not worked, please inform your veterinary surgeon.
Če opazite kakršne koli stranske učinke, tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite, da zdravilo ni delovalo, obvestite svojega veterinarja.
Care should be taken to avoid spraying into the eyes of the animal.
Treba paziti, da se izognete pršenju v oči živali.
The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm2 of affected skin per day.
Priporočeni odmerek je 1,52 µg hidrokortizon aceponata/cm2 prizadete kože na dan.
The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a low plasma availability.
Diestri so lipofilne komponente, ki zagotavljajo izboljšano penetracijo v kožo, povezano z nizko vsebnostjo v plazmi.
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.
Ker je znano, da glukokortikosteroidi upočasnjujejo rast, se mora pri mladih živalih (mlajših od 7 mesecev) zdravilo uporabljati v skladu z oceno razmerja korist/tveganje in odvisno od rednega kliničnega ocenjevanja.
Date of first authorisation: 09/01/2007 Date of latest renewal: 13/09/2011
Datum zadnjega podaljšanja dovoljenja za promet: 13/09/2011.
Hydrocortisone aceponate thus accumulates in the dog's skin allowing local efficacy at low dosage.
Na ta način se hidrokortizon aceponat v koži psa akumulira in pri nizkih odmerkih omogoča lokalno učinkovitost.
In laboratory animals, hydrocortisone aceponate is eliminated the same way as hydrocortisone (other name for endogenous cortisol) through urine and faeces.
Pri laboratorijskih živalih se hidrokortizon aceponat izloča na enak način kot hidrokortizon (drugo ime za endogeni kortizol) s sečem in blatom.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).>
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali - občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).>
In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level was observed.
Pri 12 psih, obolelih za atopičnim dermatitisom, po lokalnemi nanosu predpisanega odmerka na kožo v obdobju od 28 do 70 zaporednih dni, ni bilo opaznega učinka na sistemsko raven kortizola.
This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm. Repeat the treatment daily for 7 consecutive days.
Ta odmerek se lahko doseže z dvakratnim aktiviranjem zaporke z mehanskim pršilnikom nad tistim delom kože, ki ga je treba zdraviti in ki ustreza kvadratu 10 cm x 10 cm. Zdravljenje ponavljajte 7 zaporednih dni.
The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings.
Topilo, ki se nahaja v izdelku, lahko na določenih materialih, vključno s pobarvanimi, lakiranimi ali drugimi gospodinjskimi površinami ali oblogami, pusti madež.
In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.
V primeru, da sočasno pride do mikrobne bolezni ali parazitske infestacije, je treba psa na ustrezen način proti tej bolezni zdraviti.
In case of accidental skin contact, it is recommended to wash thoroughly with water.
V primeru nenamernega stika s kožo se priporoča temeljito izpiranje z vodo.
In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.
Zaradi pomanjkanja podatkov odsvetujemo sočasno uporabo drugih površinskih preparatov za zdravljenje istih poškodb.
SPECIAL WARNING(S), IF NECESSARY Not applicable.
POSEBNO(A) OPOZORILO(A), ČE JE/SO POTREBNO(A) Ni smiselno.
Tolerance studies using 3 and 5 times the recommended dosage for twice the recommended duration of treatment resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.
Študije tolerance, pri katerih so uporabljali 3 in 5 krat večje odmerke od priporočenih, v obdobju zdravljenja, ki je trajalo dvakrat dlje od priporočenega, so pokazale zmanjšano sposobnost proizvajanja kortizola, ki pa je bila v obdobju 7 do 9 tednov po končanem zdravljenju popolnoma reverzibilna.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY AND USE
POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
MANUFACTURER'S BATCH NUMBER Batch {number}
PROIZVAJALČEVA ŠTEVILKA SERIJE Serija {številka}
Hydrocortisone aceponate applications on the skin lesions provide rapid reduction of the skin redness, irritation and scratching while minimising the general effects.
Nanos hidrokortizon aceponat na kožne poškodbe zagotavlja hitro zmanjšanje kožne rdečine, draženja in praskanja, ob enem pa so splošni učinki minimalni.
Hydrocortisone aceponate is a dermocorticoid with a potent intrinsic glucocorticoid activity which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions observed in case of inflammatory and pruritic dermatosis.
Hidrokortizon aceponat je dermokortikoid z močnim intrinzičnim glukokortikoidnim delovanjem, ki pomeni olajšanje tako vnetja kot pruritisa, in vodi do hitrega celjenja kožnih poškodb, zaznavnih pri vnetnih in pruritičnih dermatozah.
Box containing a polyethylene terephtalate (PET) or high density polyethylene (HDPE) bottle filled with 31 ml or 76 ml of solution, closed with an aluminium screw cap or a white plastic screw cap and a pump spray.
Škatla s plastenko iz polietilen tereftalata (PET) ali polietilena visoke gostote (HDPE), ki vsebuje 31 ml ali 76 ml raztopine, zaprta z navojno zaporko iz aluminija ali z navojno zaporko iz bele plastike in zaporko z mehanskim pršilnikom.
Use only accordingly to the risk-benefit assessment by the responsible veterinarian.
Uporabite le v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription.
B POGOJI TER OMEJITVE GLEDE OSKRBE IN UPORABE Na veterinarski recept.
Hydrocortisone aceponate belongs to the diesters class of the glucocorticosteroids.
Hidrokortizon aceponat spada v diestersko skupino glukokortikosteroidov.
METHOD AND ROUTE(S) OF ADMINISTRATION Cutaneous use.
NAČIN IN POT(I) UPORABE Dermalna uporaba.
In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.
V primeru, da stanje zahteva podaljšano zdravljenje, mora odgovorni veterinar o uporabi zdravila presojati v skladu z oceno razmerja korist/tveganje.
Pack sizes:
Velikosti embalaže:
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM)
In case of eye irritation, seek medical advice.
Če pride do draženja očesa, se posvetujte z zdravnikom.
Not all pack size may be marketed.
Ni nujno, da so v prometu vsa navedena pakiranja.
Total body surface treated should not exceed a surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs.
Skupna površina telesa, ki jo zdravite, ne sme presegati površine, ki, na primer, ustreza zdravljenju obeh bočnih strani, od hrbtenice do verige seskov, vključno s pleči in stegnoma.
After topical application on the skin at the recommended therapeutic dosage and twice the recommended duration of treatment and at up to a body surface corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs, no systemic effects are observed.
Potem, ko se zdravilo na koži uporabi v priporočenih odmerkih in v obdobju, ki traja dvakrat dlje od priporočenega, na površini telesa, ki ustreza obema bočnima stranema, od hrbtenice do verige seskov, vključno s pleči in stegnoma, niso zaznavni nobeni sistemski učinki.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVAJALECBIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Sistemska absorpcija hidrokortizon aceponata je zanemarljiva; ob uporabi priporočenih odmerkov za zdravljenje psov ni verjetnosti, da se pojavijo teratogeni in fetotoksični učinki ter toksični učinki na mater.
Otherwise, use only according to the risk-benefit assessment and subject the dog to regular clinical evaluations.
Drugače se mora zdravilo uporabljati samo v skladu z oceno razmerja korist/tveganje, psa pa je treba redno klinično ocenjevati.
Carton box with a PET bottle of 31ml Carton box with a PET bottle of 76ml Carton box with a HDPE bottle of 31ml Carton box with a HDPE bottle of 76ml
Kartonasta škatla s plastenko PET 31ml Kartonasta škatla s plastenko PET 76ml Kartonasta škatla s plastenko HDPE 31ml Kartonasta škatla s plastenko HDPE 76ml
Pharmacotherapeutic group: Glucorticosteroids, dermatological preparations.
Farmakoterapevtska skupina: glukortikosteroidi, dermatiki Oznaka ATC vet: QD07AC.
HDPE bottle of 76ml: EU/2/06/069/004
HDPE plastenka po 76ml: EU/2/06/069/004
SPECIAL STORAGE CONDITIONS Not applicable.
POSEBNA NAVODILA ZA SHRANJEVANJE Ni smiselno.